Princess Margaret Cancer Centre

A five-factor risk model effectively predicted 2-year lymphedema-free survival among a cohort of patients with breast cancer, according to findings published in JAMA Network Open.

CHICAGO — The addition of subcutaneous amivantamab to lazertinib demonstrated noninferior pharmacokinetics and objective response rate compared with intravenous amivantamab, results from a phase 3 study showed.

CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.

Prophylactic IV immunoglobulin supplementation reduced the risk for severe infections by 90% among adults receiving a B-cell maturation antigen-directed bispecific antibody for treatment of multiple myeloma, study results showed.

Divarasib induced durable clinical responses among patients with KRAS G12C-positive solid tumors, according to study findings published in The New England Journal of Medicine.

Circulating tumor DNA genotyping before tissue diagnosis of suspected advanced non-small cell lung cancer resulted in significantly shorter median time to treatment compared with standard tissue testing, study results showed.

The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.

World Cancer Day will be observed Feb. 4.

Single-fraction radiation therapy reduced hepatic pain among most patients with end-stage hepatocellular carcinoma or liver metastases, according to randomized phase 3 study results presented at ASCO Gastrointestinal Cancers Symposium.

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.